We are dedicated to developing meaningful treatment options for those with skeletal dysplasias

Now enrolling children with achondroplasia from birth to <3 years old in the PROPEL Infant & Toddler trial for infigratinib.

Infigratinib is the first and only investigational therapy for achondroplasia to be awarded breakthrough therapy designation by the FDA.

Now enrolling in ACCEL, an observational study for our hypochondroplasia program.